FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 adjuvanted vaccine,CpG 1018

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Dynavax Technologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 24, 2020

            Details:

            The partners will leverage Medigen’s stable prefusion form of the SARS-CoV2 recombinant spike protein in combination with Dynavax’s advanced adjuvant CpG 1018.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Silmitasertib

            Therapeutic Area: Infections and Infectious Diseases Product Name: CX 4945

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 01, 2020

            Details:

            The latest international study led by Professor Nevan Krogan of UCSF's Quantitative Biosciences Institute found that the Casein Kinase 2 (CK2) inhibitor, Silmitasertib, displayed robust antiviral activity in treating COVID-19, in vitro.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 06, 2020

            Details:

            Adimmune had designed and produced 4 prototypes of antigens to fight Covid-19 based on its recombinant protein technology, and has tested one prototype in a BSL-3 lab at National Taiwan University.